Tumor Biology

, Volume 35, Issue 10, pp 9667–9676 | Cite as

BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma

  • Kassaporn Duangkumpha
  • Anchalee Techasen
  • Watcharin Loilome
  • Nisana Namwat
  • Raynoo Thanan
  • Narong Khuntikeo
  • Puangrat Yongvanit
Research Article


Epithelial–mesenchymal transition (EMT) is characterized by the loss of epithelial markers and the gain of mesenchymal markers. EMT is believed to be a major mechanism supporting cancer cell metastasis. The activation of EMT can be induced by various types of inflammatory cytokines including transforming growth factor β (TGF-β) whereas bone morphogenetic protein-7 (BMP-7) can inhibit this process. In this study, the up-regulation of Twist transcription factor and N-cadherin, mesenchymal marker in CCA tissues, has been demonstrated and it has been found that the high expression of Twist was significantly associated with poor prognosis of CCA patients (P = 0.010). Moreover, CCA samples showing Twist nuclear expression were significantly correlated with the up-regulation of N-cadherin (P = 0.024). These results also showed that the inflammatory mediator TGF-β induces CCA cell migration, one of the metastatic processes possibly via stimulation of Twist, N-cadherin and vimentin expression. Additionally, it has been shown that BMP-7 inhibits TGF-β-induced CCA cell migration, through inhibition of TGF-β-mediated Twist and N-cadherin expressions. These data reinforce the rationale to use BMP-7 as an EMT inhibitor to suppress the progression of CCA and might be a therapeutic approach to improve efficiency for CCA treatment.


Twist N-cadherin Metastasis Epithelial–mesenchymal transition BMP-7 Cholangiocarcinoma 



This work was supported by the Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, through the Health Cluster (SHeP-GMS), Khon Kaen University, Khon Kaen University Research Fund to PY and KD (Grant No. M54206) and the grant of Faculty of Medicine to KD (Grant No. I 56316). We express our sincere thanks to Professor James A Will for checking scientific and English improvements.

Conflicts of interest



  1. 1.
    Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48(1):308–21.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154(1):8–20.CrossRefGoogle Scholar
  5. 5.
    Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Na YR, Seok SH, Kim DJ, Han JH, Kim TH, Jung H, et al. Bone morphogenetic protein 7 induces mesenchymal-to-epithelial transition in melanoma cells, leading to inhibition of metastasis. Cancer Sci. 2009;100(11):2218–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett. 2012;586(14):1959–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial–mesenchymal transition in tumor microenvironment. Cell Biosci. 2011;1:29.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22(3):194–207.CrossRefPubMedGoogle Scholar
  10. 10.
    Fuxe J, Karlsson MC. TGF-beta-induced epithelial–mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;22(5–6):455–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Moustakas A, Heldin CH. Induction of epithelial–mesenchymal transition by transforming growth factor beta. Semin Cancer Biol. 2012;22(5–6):446–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Kang Y, Massague J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMedGoogle Scholar
  19. 19.
    Techasen A, Namwat N, Loilome W, Bungkanjana P, Khuntikeo N, Puapairoj A, et al. Tumor necrosis factor-alpha (TNF-alpha) stimulates the epithelial–mesenchymal transition regulator Snail in cholangiocarcinoma. Med Oncol. 2012;29(5):3083–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161(5):1881–91.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65(12):5153–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Yang Z, Li XJ, Luo T, Wu XT. Expression of TWIST in gastric carcinoma and its correlation with clinical significance. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42(5):625–9.PubMedGoogle Scholar
  23. 23.
    Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;34(5):2497–506.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, et al. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun. 2007;358(3):925–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.CrossRefPubMedGoogle Scholar
  27. 27.
    Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007;67(18):8742–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007;171(3):1047–57.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Bramlage CP, Tampe B, Koziolek M, Maatouk I, Bevanda J, Bramlage P, et al. Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. BMC Nephrol. 2010;11:31.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Techasen A, Loilome W, Namwat N, Duenngai K, Cha'on U, Thanan R, et al. Opisthorchis viverrini-antigen induces expression of MARCKS during inflammation-associated cholangiocarcinogenesis. Parasitol Int. 2007;61(1):140–4.CrossRefGoogle Scholar
  31. 31.
    Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, et al. Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol. 2004;35(12):1469–76.CrossRefPubMedGoogle Scholar
  33. 33.
    Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9:179.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial–mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int. 2012;111(1):30–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Shin JA, Hong OK, Lee HJ, Jeon SY, Kim JW, Lee SH, et al. Transforming growth factor-beta induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells. J Cell Biochem. 2011;112(1):179–88.CrossRefPubMedGoogle Scholar
  36. 36.
    Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006;37(4):431–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 2006;242(2):258–65.CrossRefPubMedGoogle Scholar
  38. 38.
    Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 1994;127(6 Pt 2):2021–36.CrossRefPubMedGoogle Scholar
  39. 39.
    Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology. 2010;138(4):1406–17.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9(7):964–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res. 2006;66(19):9583–90.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Kassaporn Duangkumpha
    • 1
    • 4
  • Anchalee Techasen
    • 2
    • 4
  • Watcharin Loilome
    • 1
    • 4
  • Nisana Namwat
    • 1
    • 4
  • Raynoo Thanan
    • 1
    • 4
  • Narong Khuntikeo
    • 3
    • 4
  • Puangrat Yongvanit
    • 1
    • 4
  1. 1.Department of Biochemistry, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand
  2. 2.Center for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical SciencesKhon Kaen UniversityKhon KaenThailand
  3. 3.Department of Surgery, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand
  4. 4.Liver Fluke and Cholangiocarcinoma Research CenterKhon Kaen UniversityKhon KaenThailand

Personalised recommendations